How do you ensure the accuracy and reliability of your XPO1 mutation analysis results?

Our laboratory maintains a strict regimen of quality control measures and follows validated protocols for all our molecular biology services. We utilize advanced technologies like digital PCR and next-generation sequencing, which are renowned for their high sensitivity and specificity in detecting low-frequency mutations, thereby ensuring the accuracy and reliability of our XPO1 mutation analysis results.

Can your services be used for both research and clinical applications?

While our services are primarily designed to support research and pre-clinical development, the data and insights we provide can certainly be leveraged to inform clinical strategy. Our analysis provides crucial information on biomarker status and drug efficacy that is valuable for both academic and pharmaceutical-led clinical projects.

Do you offer custom assay development for specific XPO1 variants or targets?

Yes, our team of expert scientists specializes in custom assay development. We can work directly with your research team to design and validate new analytical methods for specific XPO1 variants, or other unique targets that are of particular interest to your project, ensuring that our services are perfectly aligned with your research goals.

What is the typical turnaround time for your XPO1 analysis services?

The turnaround time for our XPO1 analysis services can vary depending on the complexity of your project and the specific services requested. We always strive to provide the most efficient service possible, and during the initial consultation, we will provide you with a realistic and transparent timeline for the completion and delivery of your final report.

Can you analyze multiple biomarkers in a single project?

Yes, while this article focuses on XPO1, our expertise extends to a wide range of biomarkers. We have the capacity and scientific know-how to design and execute projects that involve the analysis of multiple biomarkers simultaneously, which is often crucial for gaining a complete understanding of a disease's molecular profile and its progression.

How do you handle client confidentiality and data security?

We consider client confidentiality and data security to be of the utmost importance. All information and materials provided to us are handled with the highest level of care and are protected by strict confidentiality agreements. Our data management systems are secure and comply with industry standards to ensure that your intellectual property remains protected at all times.

XPO1 Analysis Service - Creative Biolabs

Biomarkers offer certain values for diagnosis, treatment efficacy monitoring, or novel therapeutic approaches development for diseases. Exportin 1 (XPO1) represents an exciting field located at the intersection between pathophysiology, diagnosis, and treatment of B cell malignancies. Creative Biolabs has developed a full suite of research services for XPO1 to evaluate its expression and function.

Introduction of XPO1

XPO1, also known as Chromosome Region Maintenance 1 (CRM1), is a pivotal nuclear transport protein. It mediates the movement of over 200 cargo molecules, including tumor suppressors, from the nucleus to the cytoplasm. This selective transport is critical for cellular homeostasis. Beyond nuclear export, XPO1 also maintains chromosome integrity and is involved in microtubule nucleation at the kinetochore, highlighting its multifaceted importance in cellular biology.

XPO1-mediated nuclear export of hundreds of proteins and multiple RNA species. (OA Literature)

Fig.1 XPO1 facilitates nuclear export of numerous proteins and diverse RNA species.¹

Dysregulation of XPO1 is a significant factor in numerous human malignancies. For decades, XPO1 dysfunction has been regarded as a diagnostic and prognostic marker and a promising anti-cancer therapeutic target. For example, in B-cell malignancies like mantle cell lymphoma (MCL), XPO1 overexpression drives uncontrolled cell proliferation and compromises chromosomal stability. Furthermore, the specific somatic mutation XPO1^E571K directly contributes to carcinogenesis and is quantifiable in tumor tissue and plasma cell-free DNA using highly sensitive techniques like digital PCR and next-generation sequencing (NGS), providing new avenues for patient stratification and personalized medicine.

XPO1 Analysis Services at Creative Biolabs

At Creative Biolabs, our specialized XPO1 analysis services are designed to provide a comprehensive and strategic advantage to our clients. We offer a holistic approach to understanding XPO1's role in disease, spanning multiple analytical platforms to meet diverse research needs. Our services are tailored to support your project at every stage, from initial discovery through to pre-clinical validation. We focus on delivering high-quality, actionable data that can accelerate your research and development timeline. Our core offerings include but are not limited to the following:

We rapidly and efficiently screen thousands of compounds to identify potential XPO1 inhibitors that can serve as promising drug candidates.

Our services provide a comprehensive evaluation of drug efficacy and safety, using both cell-based assays and preclinical animal models to assess therapeutic potential.

We precisely detect and quantify critical XPO1 variants, such as XPO1^E571K, using highly sensitive molecular techniques to support patient stratification and personalized medicine.

We investigate the complex regulatory networks involving XPO1 by analyzing its association with non-coding RNAs, offering deeper insights into its biological function and disease mechanisms.

Service Workflow

Our XPO1 analysis services follow a clear, step-by-step workflow designed for optimal project execution and timely data delivery.

01Initial Consultation

The process begins with a detailed consultation to understand your specific research goals, technical requirements, and project scope.

02Sample Submission

Clients provide their starting materials, which may include cell lines, purified DNA/RNA, or clinical samples such as tissue biopsies or plasma.

03Assay Preparation and Analysis

Our expert team prepares and runs the necessary assays. This can range from high-throughput compound screens to targeted XPO1 mutation analysis using digital PCR or NGS.

04Quality Control

Throughout the analysis, we maintain strict quality control to guarantee the accuracy and reliability of all data generated.

05Final Report Delivery

We deliver a comprehensive report that includes all raw data, detailed methodologies, and a professional interpretation of the results, empowering your team to make informed decisions for your drug development pipeline.

Applications

Patient Stratification and Diagnosis

Analysis of XPO1 expression and mutation status in patient samples can serve as a powerful tool for diagnosing specific cancer subtypes and stratifying patients for clinical trials. This allows for the selection of individuals most likely to benefit from XPO1-targeting therapies.

Therapeutic Target Validation

Our services provide critical data for validating XPO1 as a therapeutic target in novel disease models. By correlating XPO1 dysregulation with disease phenotype, researchers can build a strong case for developing and testing new selective inhibitors of nuclear export (SINEs).

Monitoring Treatment Response

Longitudinal monitoring of XPO1 expression and mutation load in liquid biopsy samples provides a non-invasive method for tracking disease progression and evaluating the efficacy of anti-cancer therapies. A decrease in the mutant XPO1^E571K allele frequency, for example, could indicate a positive response to treatment.

Novel Drug Discovery

The ability to screen thousands of compounds against XPO1 provides a clear advantage in drug discovery. Our high-throughput screening assays help researchers to efficiently identify and optimize lead compounds for further development.

Service Highlights

FAQs

If you are interested in our analysis services at Creative Biolabs, please feel free to contact us for more information.